We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+50.74%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.11B
AUM Growth
+$318M
Cap. Flow
+$94.6M
Cap. Flow %
8.53%
Top 10 Hldgs %
61.72%
Holding
56
New
18
Increased
10
Reduced
10
Closed
12
Avg Time Held Equity + Options
3.3 quarters
Top 10 Avg Time Held Equity + Options
4 quarters
Top 20 Avg Time Held Equity + Options
3.4 quarters
Avg Time Held Equity only
3.2 quarters
Top 10 Avg Time Held Equity only
4.5 quarters
Top 20 Avg Time Held Equity only
3.2 quarters

Top Buys

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$46.5M
2
ARVN icon
Arvinas
ARVN
+$39.2M
3
ASMB icon
Assembly Biosciences
ASMB
+$35.2M
4
IPHA icon
Innate Pharma
IPHA
+$27.9M
5
MRUS icon
Merus
MRUS
+$25M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$69.3M
2
ARGX icon
argenx
ARGX
+$44.5M
3
SLDB icon
Solid Biosciences
SLDB
+$34.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$14.3M
5
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$8.42M

Sector Composition

Rank Sector Weight
1 Healthcare 95%
2 Miscellaneous 5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PRTA icon
1
Prothena Corp
PRTA
$429M
$149M 13.45%
9,426,640
– –
2018 Q4
4 quarters
XNCR icon
2
Xencor
XNCR
$1.75B
$86M 7.75%
2,501,557
– –
2018 Q4
4 quarters
DRNA
3
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$79.9M 7.2%
3,627,597
-335,381
-8% -$6.75M
2017 Q1
11 quarters
KYNB icon
4
Kyntra Bio
KYNB
$23.8M
$64M 5.77%
59,689
+7,937
+15% +$8.1M
2014 Q4
20 quarters
KURA icon
5
Kura Oncology
KURA
$874M
$58.3M 5.26%
4,241,953
+200,000
+5% +$2.96M
2015 Q4
16 quarters
IRWD icon
6
Ironwood Pharmaceuticals
IRWD
$593M
$58.2M 5.24%
4,371,408
-300,000
-6% -$3.31M
2015 Q4
16 quarters
ARVN icon
7
Arvinas
ARVN
$447M
$55M 4.96%
+1,339,069
New +$39.2M
2019 Q4
0 quarters
ASMB icon
8
Assembly Biosciences
ASMB
$414M
$48.9M 4.4%
199,022
+190,972
+2,372% +$35.2M
2019 Q3
1 quarter
NGNE icon
9
Neurogene
NGNE
$431M
$48.2M 4.35%
195,794
+82,500
+73% +$8.22M
2018 Q2
6 quarters
MORF icon
10
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$37M 3.33%
2,154,845
-6,675
-0.3% -$104K
2019 Q2
2 quarters
PRVL
11
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$35.6M 3.21%
2,248,306
-144,250
-6% -$1.84M
2019 Q2
2 quarters
ARGX icon
12
argenx
ARGX
$50.5B
$32.4M 2.92%
202,117
-329,048
-62% -$44.5M
2018 Q4
4 quarters
ANAB icon
13
AnaptysBio
ANAB
$1.36B
$31.9M 2.88%
+1,966,100
New +$46.5M
2019 Q4
0 quarters
IPHA icon
14
Innate Pharma
IPHA
$164M
$29.3M 2.64%
+4,545,454
New +$27.9M
2019 Q4
0 quarters
KYNB icon
15
CALL
Kyntra Bio
KYNB
$23.8M
$29M 2.62%
27,060
+960
+4% +$980K
2017 Q4
8 quarters
BMRN icon
16
CALL
BioMarin Pharmaceuticals
BMRN
$10.5B
$26.4M 2.38%
+312,500
New +$23.6M
2019 Q4
0 quarters
MRUS icon
17
DELISTED
Merus
MRUS
$24.2M 2.18%
1,718,200
+1,552,600
+938% +$25M
2019 Q3
1 quarter
BCEL
18
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$22.9M 2.07%
1,481,411
– –
2019 Q2
2 quarters
ACAD icon
19
Acadia Pharmaceuticals
ACAD
$3.21B
$21.4M 1.93%
+500,000
New +$21.8M
2019 Q4
0 quarters
CHMA
20
DELISTED
Chiasma, Inc. Common Stock
CHMA
$15.1M 1.36%
3,043,827
– –
2018 Q3
5 quarters
HARP
21
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$13.4M 1.21%
90,855
-55,487
-38% -$8.42M
2019 Q1
3 quarters
SAGE icon
22
DELISTED
Sage Therapeutics
SAGE
$12.5M 1.13%
+173,364
New +$21.3M
2019 Q4
0 quarters
RARE icon
23
Ultragenyx Pharmaceutical
RARE
$1.47B
$11.2M 1.01%
261,554
+200,000
+325% +$8.25M
2019 Q1
3 quarters
RNAC icon
24
Cartesian Therapeutics
RNAC
$199M
$10.9M 0.99%
+153,257
New +$7.39M
2019 Q4
0 quarters
XCUR icon
25
Exicure
XCUR
$7.53M
$10.1M 0.91%
23,628
-13,140
-36% -$5.38M
2019 Q3
1 quarter
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2019 Portfolio in Review

As of Q4 2019, EcoR1 Capital held 56 positions worth $1.11B, up 40% from $792M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

EcoR1 Capital deployed $94.6M of net new capital in Q4 2019, opening 18 new positions and adding to 10 existing holdings. Its largest new stake was AnaptysBio: 1,966,100 shares worth $31.9M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was argenx, an estimated $44.5M trimmed.

  • EcoR1 Capital's largest Q4 2019 buy was AnaptysBio: 1,966,100 shares worth $31.9M.
  • EcoR1 Capital added most to Assembly Biosciences in Q4 2019, an estimated $35.2M increase.
  • EcoR1 Capital's biggest Q4 2019 reduction was argenx, cutting an estimated $44.5M.
  • EcoR1 Capital fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $69.3M.
  • EcoR1 Capital's ten largest holdings make up 62% of its $1.11B portfolio in Q4 2019.
  • EcoR1 Capital opened 18 new positions and closed 12 in Q4 2019.
  • EcoR1 Capital's portfolio value rose 40% quarter-over-quarter to $1.11B.

Based on EcoR1 Capital's 13F filing for Q4 2019, filed 14 Feb 2020.